Guarantor Financial Information (Tables)

12 Months Ended

Apr. 24, 2015

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 24, 2015

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	1,261		$	—		$	20,261		$	(1,261	)	$	20,261

Costs and expenses:
Cost of products sold	—			1,234			—			5,969			(894		)	6,309
Research and development expense	—			390			—			1,250			—			1,640
Selling, general, and administrative expense	—			535			—			6,369			—			6,904
Special (gains) charges, net	—			—			—			(38		)	—			(38		)
Restructuring charges, net	—			—			—			237			—			237
Certain litigation charges, net	—			—			—			42			—			42
Acquisition-related items	—			—			—			550			—			550
Amortization of intangible assets	—			11			—			722			—			733
Other (income) expense, net	(108		)	(712		)	—			938			—			118
Operating profit	108			(197		)	—			4,222			(367		)	3,766

Interest income	—			—			(170		)	(386		)	170			(386		)
Interest expense	—			706			—			130			(170		)	666
Interest expense (income), net	—			706			(170		)	(256		)	—			280
Equity in net income of subsidiaries	(2,578		)	(3,629		)	(2,408		)	—			8,615			—
Income from operations before income taxes	2,686			2,726			2,578			4,478			(8,982		)	3,486
Provision (benefit) for income taxes	11			(330		)	—			1,268			(138		)	811
Net income	2,675			3,056			2,578			3,210			(8,844		)	2,675
Other comprehensive loss, net of tax	(587		)	(587		)	(587		)	(587		)	1,761			(587		)
Total comprehensive income	$	2,088		$	2,469		$	1,991		$	2,623		$	(7,083	)	$	2,088

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 25, 2014

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—	$	1,155		$	—	$	17,005		$	(1,155	)	$	17,005

Costs and expenses:
Cost of products sold	—		1,123			—		4,353			(1,143		)	4,333
Research and development expense	—		380			—		1,097			—			1,477
Selling, general, and administrative expense	—		617			—		5,230			—			5,847
Special charges	—		—			—		40			—			40
Restructuring charges, net	—		—			—		78			—			78
Certain litigation charges, net	—		—			—		770			—			770
Acquisition-related items	—		—			—		117			—			117
Amortization of intangible assets	—		12			—		337			—			349
Other (income) expense, net	—		(1,219		)	—		1,400			—			181
Operating profit	—		242			—		3,583			(12		)	3,813

Interest income	—		(5		)	—		(266		)	—			(271		)
Interest expense	—		317			—		62			—			379
Interest expense (income), net	—		312			—		(204		)	—			108
Equity in net income of subsidiaries	—		(3,560		)	—		—			3,560			—
Income from operations before income taxes	—		3,490			—		3,787			(3,572		)	3,705
Provision for income taxes	—		425			—		227			(12		)	640
Net income	—		3,065			—		3,560			(3,560		)	3,065
Other comprehensive loss, net of tax	—		(105		)	—		(105		)	105			(105		)
Total comprehensive income	$	—	$	2,960		$	—	$	3,455		$	(3,455	)	$	2,960

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 26, 2013

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—	$	1,090		$	—	$	16,590		$	(1,090	)	$	16,590

Costs and expenses:
Cost of products sold	—		1,057			—		4,147			(1,078		)	4,126
Research and development expense	—		421			—		1,136			—			1,557
Selling, general, and administrative expense	—		542			—		5,156			—			5,698
Special charges	—		—			—		—			—			—
Restructuring charges, net	—		—			—		172			—			172
Certain litigation charges, net	—		—			—		245			—			245
Acquisition-related items	—		—			—		(49		)	—			(49		)
Amortization of intangible assets	—		14			—		317			—			331
Other (income) expense, net	—		(1,136		)	—		1,244			—			108
Operating profit	—		192			—		4,222			(12		)	4,402

Interest income	—		—			—		(237		)	—			(237		)
Interest expense	—		329			—		59			—			388
Interest expense (income), net	—		329			—		(178		)	—			151
Equity in net income of subsidiaries	—		(3,945		)	—		—			3,945			—
Income from operations before income taxes	—		3,808			—		4,400			(3,957		)	4,251
Provision for income taxes	—		341			—		455			(12		)	784
Net income	—		3,467			—		3,945			(3,945		)	3,467
Other comprehensive loss, net of tax	—		(19		)	—		(19		)	19			(19		)
Total comprehensive income	$	—	$	3,448		$	—	$	3,926		$	(3,926	)	$	3,448

Consolidating Statement of Comprehensive Income

Fiscal Year Ended April 24, 2015

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Net sales	$	—		$	—		$	—		$	20,261		$	—		$	20,261

Costs and expenses:
Cost of products sold	—			—			—			6,309			—			6,309
Research and development expense	—			—			—			1,640			—			1,640
Selling, general, and administrative expense				—			21			6,883			—			6,904
Special (gains) charges, net	—			—			—			(38		)	—			(38		)
Restructuring charges, net	—			—			—			237			—			237
Certain litigation charges, net	—			—			—			42			—			42
Acquisition-related items	—			—			—			550			—			550
Amortization of intangible assets	—			—			—			733			—			733
Other (income) expense, net	(108		)	1			26			199			—			118
Operating profit	108			(1		)	(47		)	3,706			—			3,766

Interest income	—			(149		)	(170		)	(386		)	319			(386		)
Interest expense	—			29			—			956			(319		)	666
Interest (income) expense, net	—			(120		)	(170		)	570			—			280
Equity in net income of subsidiaries	(2,578		)	626			(2,410		)	—			4,362			—
Income (loss) from operations before income taxes	2,686			(507		)	2,533			3,136			(4,362		)	3,486
Provision for income taxes	11			—			—			800			—			811
Net income (loss)	2,675			(507		)	2,533			2,336			(4,362		)	2,675
Other comprehensive loss, net of tax	(587		)	(587		)	(587		)	(587		)	1,761			(587		)
Total comprehensive income (loss)	$	2,088		$	(1,094	)	$	1,946		$	1,749		$	(2,601	)	$	2,088

Condensed Consolidating Balance Sheet

Fiscal Year Ended April 24, 2015

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	263	$	1,071	$	170	$	3,339	$	—		$	4,843
Investments	—		—		—		14,637		—			14,637
Accounts receivable, net	—		—		—		5,112		—			5,112
Inventories	—		165		—		3,298		—			3,463
Intercompany receivable	259		146,373		—		150,679		(297,311		)	—
Tax assets	—		770		—		729		(164		)	1,335
Prepaid expenses and other current assets	4		128		—		1,322		—			1,454
Total current assets	526		148,507		170		179,116		(297,475		)	30,844
Property, plant and equipment, net	—		976		—		3,753		(30		)	4,699
Goodwill	—		1,607		—		38,923		—			40,530
Other intangible assets, net	—		39		—		28,062		—			28,101
Long-term tax assets	—		643		—		559		(428		)	774
Investment in subsidiaries	70,255		41,218		64,335		—		(175,808		)	—
Intercompany loans receivable	3,000		6,516		10,000		10,218		(29,734		)	—
Other assets	—		678		—		1,059		—			1,737
Total assets	$	73,781	$	200,184	$	74,505	$	261,690	$	(503,475	)	$	106,685
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—	$	1,110	$	—	$	1,324	$	—		$	2,434
Accounts payable	—		261		—		1,349		—			1,610
Intercompany payable	20,506		135,091		—		141,714		(297,311		)	—
Accrued compensation	1		490		—		1,120		—			1,611
Accrued income taxes	41		371		—		523		—			935
Deferred tax liabilities	3		—		—		280		(164		)	119
Other accrued expenses	—		600		—		1,894		(30		)	2,464
Total current liabilities	20,551		137,923		—		148,204		(297,505		)	9,173
Long-term debt	—		29,004		—		4,748		—			33,752
Long-term accrued compensation and retirement benefits	—		965		—		570		—			1,535
Long-term accrued income taxes	—		1,450		—		1,026		—			2,476
Long-term intercompany loans payable	—		10,218		10,000		9,516		(29,734		)	—
Long-term deferred tax liabilities	—		—		—		5,128		(428		)	4,700
Other long-term liabilities	—		207		—		1,612		—			1,819
Total liabilities	20,551		179,767		10,000		170,804		(327,667		)	53,455
Shareholders’ equity	53,230		20,417		64,505		90,886		(175,808		)	53,230
Total liabilities and shareholders’ equity	$	73,781	$	200,184	$	74,505	$	261,690	$	(503,475	)	$	106,685

Condensed Consolidating Balance Sheet

Fiscal Year Ended April 25, 2014

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	264	$	—	$	1,139	$	—		$	1,403
Investments	—		—		—		12,838		—			12,838
Accounts receivable, net	—		—		—		3,811		—			3,811
Inventories	—		154		—		1,571		—			1,725
Intercompany receivable	—		43,377		—		51,593		(94,970		)	—
Tax assets	—		602		—		193		(59		)	736
Prepaid expenses and other current assets	—		479		—		597		(379		)	697
Total current assets	—		44,876		—		71,742		(95,408		)	21,210
Property, plant and equipment, net	—		954		—		1,461		(23		)	2,392
Goodwill	—		1,565		—		9,028		—			10,593
Other intangible assets, net	—		51		—		2,235		—			2,286
Long-term tax assets	—		435		—		252		(387		)	300
Investment in subsidiaries			36,943				—		(36,943		)	—
Intercompany loans receivable	—		20		—		273		(293		)	—
Other assets	—		573		—		589		—			1,162
Total assets	$	—	$	85,417	$	—	$	85,580	$	(133,054	)	$	37,943
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—	$	1,262	$	—	$	351	$	—		$	1,613
Accounts payable	—		201		—		541		—			742
Intercompany payable	—		51,593		—		43,377		(94,970		)	—
Accrued compensation	—		405		—		610		—			1,015
Accrued income taxes	—		144		—		20		—			164
Deferred tax liabilities	—		—		—		78		(59		)	19
Other accrued expenses	—		—		—		2,408		(402		)	2,006
Total current liabilities	—		53,605		—		47,385		(95,431		)	5,559
Long-term debt	—		10,177		—		138		—			10,315
Long-term accrued compensation and retirement benefits	—		487		—		175		—			662
Long-term accrued income taxes	—		1,315		—		28		—			1,343
Long-term intercompany loans payable	—		273		—		20		(293		)	—
Long-term deferred tax liabilities	—		—		—		773		(387		)	386
Other long-term liabilities	—		117		—		118		—			235
Total liabilities	—		65,974		—		48,637		(96,111		)	18,500
Shareholders’ equity	—		19,443		—		36,943		(36,943		)	19,443
Total liabilities and shareholders’ equity	$	—	$	85,417	$	—	$	85,580	$	(133,054	)	$	37,943

Condensed Consolidating Balance Sheet

Fiscal Year Ended April 24, 2015

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (CIFSA)		Subsidiary Guarantors		Subsidiary Non-guarantors		Consolidating Adjustments			Total
ASSETS
Current assets:
Cash and cash equivalents	$	263	$	728	$	170	$	3,682	$	—		$	4,843
Investments	—		—		—		14,637		—			14,637
Accounts receivable, net	—		—		—		5,112		—			5,112
Inventories	—		—		—		3,463		—			3,463
Intercompany receivable	259		—		269		20,508		(21,036		)	—
Tax assets	—		—		—		1,335		—			1,335
Prepaid expenses and other current assets	4		—		6		1,444		—			1,454
Total current assets	526		728		445		50,181		(21,036		)	30,844
Property, plant and equipment, net	—		—		1		4,728		(30		)	4,699
Goodwill	—		—		—		40,530		—			40,530
Other intangible assets, net	—		—		—		28,101		—			28,101
Long-term tax assets	—		—		—		774		—			774
Investment in subsidiaries	70,255		7,040		64,335		—		(141,630		)	—
Intercompany loans receivable	3,000		7,401		11,303		6,372		(28,076		)	—
Other assets	—		—		—		1,737		—			1,737
Total assets	$	73,781	$	15,169	$	76,084	$	132,423	$	(190,772	)	$	106,685
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	—	$	1,002	$	—	$	1,432	$	—		$	2,434
Accounts payable	—		—		2		1,608		—			1,610
Intercompany payable	20,506		—		280		250		(21,036		)	—
Accrued compensation	1		—		—		1,610		—			1,611
Accrued income taxes	41		—		—		894		—			935
Deferred tax liabilities	3		—		—		116		—			119
Other accrued expenses	—		610		1		1,883		(30		)	2,464
Total current liabilities	20,551		1,612		283		7,793		(21,066		)	9,173
Long-term debt	—		4,580		—		29,172		—			33,752
Long-term accrued compensation and retirement benefits	—		—		—		1,535		—			1,535
Long-term accrued income taxes	—		—		—		2,476		—			2,476
Long-term intercompany loans payable	—		8,385		10,002		9,689		(28,076		)	—
Long-term deferred tax liabilities	—		—		—		4,700		—			4,700
Other long-term liabilities	—		—		—		1,819		—			1,819
Total liabilities	20,551		14,577		10,285		57,184		(49,142		)	53,455
Shareholders’ equity	53,230		592		65,799		75,239		(141,630		)	53,230
Total liabilities and shareholders’ equity	$	73,781	$	15,169	$	76,084	$	132,423	$	(190,772	)	$	106,685

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 24, 2015

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by operating activities	$	26		$	1,649		$	170	$	3,057		$	—		$	4,902
Investing Activities:
Acquisitions, net of cash acquired	(9,700		)	(65		)	—		(5,119		)	—			(14,884		)
Additions to property, plant, and equipment	—			—			—		(571		)	—			(571		)
Purchases of marketable securities	—			—			—		(7,582		)	—			(7,582		)
Sales and maturities of marketable securities	—			—			—		5,890			—			5,890
Net decrease in intercompany loans	—			(16,996		)	—		55			16,941			—
Other investing activities, net	—			—			—		89			—			89
Net cash used in investing activities	(9,700		)	(17,061		)	—		(7,238		)	16,941			(17,058		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—		(85		)	—			(85		)
Change in short-term borrowings, net	—			—			—		(1		)	—			(1		)
Repayment of short-term borrowings (maturities greater than 90 days)	—			(150		)	—		—			—			(150		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—			150			—		—			—			150
Issuance of long-term debt	—			19,942			—		—			—			19,942
Payments on long-term debt	—			(1,268		)	—		—			—			(1,268		)
Dividends to shareholders	(435		)	(902		)	—		—			—			(1,337		)
Issuance of ordinary shares	172			477			—		—			—			649
Repurchase of ordinary shares	(300		)	(1,620		)	—		—			—			(1,920		)
Net intercompany loan borrowings (repayments)	10,500			(55		)	—		6,496			(16,941		)	—
Other financing activities	—			—			—		(31		)	—			(31		)
Net cash provided by financing activities	9,937			16,574			—		6,379			(16,941		)	15,949
Effect of exchange rate changes on cash and cash equivalents	—			(355		)	—		2			—			(353		)
Net change in cash and cash equivalents	263			807			170		2,200			—			3,440
Cash and cash equivalents at beginning of period	—			264			—		1,139			—			1,403
Cash and cash equivalents at end of period	$	263		$	1,071		$	170	$	3,339		$	—		$	4,843

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 25, 2014

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by operating activities	$	—	$	1,384		$	—	$	3,575		$	—		$	4,959
Investing Activities:
Acquisitions, net of cash acquired	—		—			—		(385		)	—			(385		)
Additions to property, plant, and equipment	—		(154		)	—		(242		)	—			(396		)
Purchases of marketable securities	—		—			—		(10,895		)	—			(10,895		)
Sales and maturities of marketable securities	—		—			—		8,111			—			8,111
Net decrease in intercompany loans	—		1			—		(12		)	11			—
Increase in investment in subsidiary	—		—			—		—			—			—
Other investing activities, net	—		—			—		(29		)	—			(29		)
Net cash used in investing activities	—		(153		)	—		(3,452		)	11			(3,594		)
Financing Activities:
Acquisition-related contingent consideration	—		—			—		(1		)	—			(1		)
Change in short-term borrowings, net	—		—			—		127			—			127
Repayment of short-term borrowings (maturities greater than 90 days)	—		(1,301		)	—		—			—			(1,301		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—		1,045			—		131			—			1,176
Issuance of long-term debt	—		1,994			—		—			—			1,994
Payments on long-term debt	—		(565		)	—		—			—			(565		)
Dividends to shareholders	—		(1,116		)	—		—			—			(1,116		)
Issuance of ordinary shares	—		1,307			—		—			—			1,307
Repurchase of ordinary shares	—		(2,553		)	—		—			—			(2,553		)
Net intercompany loan borrowings (repayments)	—		12			—		(1		)	(11		)	—
Other financing activities	—		14			—		—			—			14
Net cash (used in) provided by financing activities	—		(1,163		)	—		256			(11		)	(918		)
Effect of exchange rate changes on cash and cash equivalents	—		—			—		37			—			37
Net change in cash and cash equivalents	—		68			—		416			—			484
Cash and cash equivalents at beginning of period	—		196			—		723			—			919
Cash and cash equivalents at end of period	$	—	$	264		$	—	$	1,139		$	—		$	1,403

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 26, 2013

Medtronic 2015 Senior Notes and Medtronic Outstanding Notes



(in millions)	Parent Company Guarantor (Medtronic plc)		Subsidiary Issuer (Medtronic, Inc.)			Subsidiary Guarantors		Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by operating activities	$	—	$	2,298		$	—	$	2,644		$	—		$	4,942
Investing Activities:
Acquisitions, net of cash acquired	—		—			—		(820		)	—			(820		)
Additions to property, plant, and equipment	—		(119		)	—		(338		)	—			(457		)
Purchases of marketable securities	—		—			—		(12,321		)	—			(12,321		)
Sales and maturities of marketable securities	—		—			—		10,511			—			10,511
Net decrease in intercompany loans	—		—			—		17			(17		)	—
Increase in investment in subsidiary	—		—			—		—			—			—
Other investing activities, net	—		—			—		(14		)	—			(14		)
Net cash used in investing activities	—		(119		)	—		(2,965		)	(17		)	(3,101		)
Financing Activities:
Acquisition-related contingent consideration	—		—			—		(18		)	—			(18		)
Change in short-term borrowings, net	—		(699		)	—		(21		)	—			(720		)
Repayment of short-term borrowings (maturities greater than 90 days)	—		(2,700		)	—		—			—			(2,700		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—		2,628			—		—			—			2,628
Issuance of long-term debt	—		2,980			—		—			—			2,980
Payments on long-term debt	—		(2,214		)	—		—			—			(2,214		)
Dividends to shareholders	—		(1,055		)	—		—			—			(1,055		)
Issuance of ordinary shares	—		267			—		—			—			267
Repurchase of ordinary shares	—		(1,247		)	—		—			—			(1,247		)
Net intercompany loan borrowings (repayments)	—		(17		)	—		—			17			—
Other financing activities	—		(22		)	—		—			—			(22		)
Net cash used in financing activities	—		(2,079		)	—		(39		)	17			(2,101		)
Effect of exchange rate changes on cash and cash equivalents	—		—			—		7			—			7
Net change in cash and cash equivalents	—		100			—		(353		)	—			(253		)
Cash and cash equivalents at beginning of period	—		96			—		1,076			—			1,172
Cash and cash equivalents at end of period	$	—	$	196		$	—	$	723		$	—		$	919

Condensed Consolidating Statement of Cash Flows

Fiscal Year Ended April 24, 2015

CIFSA Senior Notes



(in millions)	Parent Company Guarantor (Medtronic plc)			Subsidiary Issuer (CIFSA)			Subsidiary Guarantors			Subsidiary Non-guarantors			Consolidating Adjustments			Total
Operating Activities:
Net cash provided by (used in) operating activities	$	26		$	(205	)	$	1,472		$	4,709		$	(1,100	)	$	4,902
Investing Activities:
Acquisitions, net of cash acquired	(9,700		)	—			—			(5,184		)	—			(14,884		)
Additions to property, plant, and equipment	—			—			(1		)	(570		)	—			(571		)
Purchases of marketable securities	—			—			—			(7,582		)	—			(7,582		)
Sales and maturities of marketable securities	—			—			—			5,890			—			5,890
Net decrease in intercompany loans	—			(7,401		)	(1,303		)	(18,887		)	27,591			—
Other investing activities, net	—			—			—			89			—			89
Net cash used in investing activities	(9,700		)	(7,401		)	(1,304		)	(26,244		)	27,591			(17,058		)
Financing Activities:
Acquisition-related contingent consideration	—			—			—			(85		)	—			(85		)
Change in short-term borrowings, net	—			—			—			(1		)	—			(1		)
Repayment of short-term borrowings (maturities greater than 90 days)	—			—			—			(150		)	—			(150		)
Proceeds from short-term borrowings (maturities greater than 90 days)	—			—			—			150			—			150
Issuance of long-term debt	—			—			—			19,942			—			19,942
Payments on long-term debt	—			(51		)	—			(1,217		)	—			(1,268		)
Dividends to shareholders	(435		)	—			—			(902		)	—			(1,337		)
Issuance of ordinary shares	172			—			—			477			—			649
Repurchase of ordinary shares	(300		)	—			—			(1,620		)	—			(1,920		)
Net intercompany loan borrowings (repayments)	10,500			8,385			2			8,704			(27,591		)	—
Intercompany dividend paid	—			—			—			(1,100		)	1,100			—
Other financing activities	—			—			—			(31		)	—			(31		)
Net cash provided by financing activities	9,937			8,334			2			24,167			(26,491		)	15,949
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(353		)	—			(353		)
Net change in cash and cash equivalents	263			728			170			2,279			—			3,440
Cash and cash equivalents at beginning of period	—			—			—			1,403			—			1,403
Cash and cash equivalents at end of period	$	263		$	728		$	170		$	3,682		$	—		$	4,843